Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rhana Therapeutics is a biotechnology company that developed the Cymerus platform, a proprietary technology for the mass production of mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs). This technology addresses the scalability challenges of traditional bone marrow-derived MSC therapies by providing a consistent and virtually limitless source of cells. The company was acquired by Cynata Therapeutics in 2013, which has since advanced the Cymerus-derived MSCs into clinical trials for indications such as graft-versus-host disease (GvHD), osteoarthritis, and respiratory distress. Rhana's foundational work remains the core of Cynata's therapeutic pipeline and manufacturing strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RHANA Corporation.